Archive

Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

SGLT2 inhibitors gave consistent heart failure and kidney benefit; GLP-1 receptor agonists gave strong atherosclerotic cardiovascular benefit and greater weight loss. Combination therapy looked complementary but was not proven superior to selected monotherapy.

Endocrinology · Cureus · 2d

Interra Health now supports CMS’ GLP-1 Bridge Program

If you prescribe GLP-1s, this platform flags patients who may qualify for the CMS Bridge Program, easing access and cost barriers.

Endocrinology · Fierce Healthcare · 3d

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

A new Lilly-backed spinout with $50M may bring a next-gen diabetes option—watch for efficacy or safety gains over current therapies.

Endocrinology · Fierce Biotech · 3d

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

A new GLP-1 for obesity and diabetes is entering Europe; watch for pricing and supply competition that may affect your patients' access.

Endocrinology · Fierce Biotech · 8d

Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment

For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.

Endocrinology · ETHealthworld · 8d

Vitamin D3 more effective than Vitamin D2 in maintaining muscle, heart health: ICMR-NIN study

Prefer D3 supplements for patients needing vitamin D, as D2 may inadequately protect muscle and cardiac structure.

Endocrinology · ETHealthworld · 10d

Compounded GLP-1 Drugs Remain Prevalent After Drug Shortage

Patients may still use unregulated compounded GLP-1s; verify sources and counsel on safety now that branded options are available.

Endocrinology · JAMA · 11d

Solera Health adds Noom to weight management offerings

Expands patient access to structured weight-loss programs and GLP-1 support, potentially improving adherence and outcomes in obesity care.

Endocrinology · Fierce Healthcare · 12d

Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data

A UCN2 analog may preserve lean muscle during weight loss—unlike GLP-1s—so watch for trials if you manage obesity.

Endocrinology · Fierce Biotech · 28 Aug

FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar

For your diabetic patients, this single wearable replaces separate glucose and ketone sensors, enabling earlier detection of ketoacidosis risk.

Endocrinology · FDA — Press Announcements · 25 Aug